HLA class II-restricted T cell epitopes in public neoantigens of ESR1 and PIK3CA in breast cancer
Abstract Background The high occurrence of treatment resistance in patients with hormone receptor-positive (HR +) breast cancer is a global health concern. Thus, effective immunotherapy must be developed. The public neoantigens, estrogen receptor 1 (ESR1) and phosphatidylinositol-4,5-bisphosphate 3-...
Saved in:
| Main Authors: | Yukari Ando, Hiroko Miyadera, Hiroko Bando, Sachie Hashimoto, Emiko Noguchi, Hisato Hara |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-13992-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Shared neoantigens for cancer immunotherapy
by: Anastasia Goloudina, et al.
Published: (2025-06-01) -
Neoantigens: new hope for cancer therapy
by: Yitong Hu, et al.
Published: (2025-03-01) -
Identification of neoantigen epitopes in cervical cancer by multi-omics analysis
by: Jing Yuan, et al.
Published: (2025-08-01) -
Neoantigen immunotherapy: a novel treatment for bladder cancer
by: Ruiyang Lv, et al.
Published: (2025-01-01) -
HLA class II neoantigen presentation for CD4+ T cell surveillance in HLA class II-negative colorectal cancer
by: Satoru Matsumoto, et al.
Published: (2024-12-01)